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Abstract 
Reaction of nitric oxide (NO’) with superoxide radical generates ~roxynitrite, which can decompose to products that nitrate aromatic amino acids. 
Such nitro-aromatics may be ‘markers’ of NW-dependent oxidative damage. Blood serum and synovial fluid from patients with the inffammato~ 
joint disease rheumatoid arthritis contain 3nitrotyrosine. By contrast, body fluids from normal subjects and patients with osteoarthritis contain no 
detectable 3-nitrotyrosine; much lower levels were found in serum from patients in the early stages of rheumatoid arthritis. This is evidence that NO 
plays a role in joint damage in rheumatoid arthritis. 
Key words: Peroxynitrite; Nitric oxide; Nitrotyrosine; Oxidative damage; Rheumatoid arthritis 
1. Introduction 
The free radical gas nitric oxide (NO’) performs many 
useful functions when produced in vivo, e.g. by neurones 
and endothelial cells [I]. However, excess NO’ can exert 
cytotoxic and cytostatic effects [1,2]. These may involve 
both direct toxicity, e.g. by reaction of NO’ with mito- 
chondrial iron-sulphur proteins [3], and the interaction 
of NO’ with other free radicals. Nitric oxide reacts with 
a very high rate constant with superoxide radical (O,‘-) 
to give perox~itrite, ONOO- [4-63. Peroxynitrite can be 
directly cytotoxic [7] and it can also decompose to give 
a range of products, including hydroxyl radicals (OH’) 
and nitronium ion (NO,‘) [5-lo]. Addition of peroxyni- 
trite to biological fluids leads to nitration of aromatic 
amino acid residues, and the presence of these may be a 
‘marker’ of peroxynitrite-mediated (i.e. NO’-dependent) 
damage in vivo [8-l 11. 
In chronic inflammatory diseases uch as rheumatoid 
arthritis (RA) there is excess production of oxygen free 
radicals, that contributes to tissue damage [12,131. Nitric 
oxide has often been suggested to participate in joint 
damage [2,1417] and inhibitors of NO’ synthetase sup- 
press arthritis in mice [15]. However, there is no direct 
evidence that NW-mediated damage occurs in human 
inflammato~ joint disease. If it could be shown to occur, 
it might provide a route for the development of new 
therapies. 
*Corresponding author. 
In the present paper, we show that levels of 3-nitro- 
tyrosine, which can be produced by NW-dependent oxi- 
dative damage [8-l 11, are elevated in patients with RA. 
This methodology could also be used to implicate No’- 
mediated damage in other human diseases, and to test 
the ability of NO’ synthetase inhibitors to ameliorate 
such damage. 
2. Materials and methods 
2.1. Patients 
Patients with active RA (criteria of the American Rheumatological 
Association) or osteoarthritis were examined and the diagnoses con- 
firmed by at least two experienced rheumatologists. Joint aspiration of 
synovial fluid was performed only when medically necessary. Fluids 
were centrifuged at 1000 rpm for 10 min to sediment cells and the 
supematants analyzed for nitrotyrosines after filtration through Ami- 
con Centrifree micro partition devices at 4,000 x g for I h at 20°C. In 
some cases, parallel blood samples were collected and allowed to clot 
to produce serum, which was treated in the same way. 
2.2. Chemicals 
3-Nitro-r.-tyrosine and other reagents were purchased from Sigma 
Chemical Co. (Poole, Dorset, UK). 
2.3. HPLC analysis of nitro-cornpo~~ 
HPLC separation of 3-nitro+tyrosine was achieved using an HPLC 
technology Nucleocil 5~ C-18 column (25 cm x 4.6 mm) with a guard 
column (Hibar from Merck Ltd., Poole, Dorset, UK; with a C-8 car- 
tridge). The eluant was 500 mM KH,PO,-F&PO, (pH 3.01) with 10% 
methanol (v/v) at a flow rate of 1 ml/min through a Polymer Laborato- 
ries Ltd. isocratic pump and an Ultraviolet Detector set at 274 nm 
(sensitivity 0.01). Using this technique the detection limit is 0.2 PM. 
Identification of the peak was carried out on the basis of the retention 
time of authentic 3-t_-nitrotyrosine, ‘spiking’ experiments, and compar- 
ison of UV and mass spectral (direct probe) analysis, using a KRATOS 
model MS 890MS with a KRATOS DS90 data system. 
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Fig. 1. HPLC separation of (A) a standard aqueous mixture of o-tyrosine (o-Tyr, 5 PM), m-tyrosine (m-Tyr, 5 PM), p-tyrosine @-Tyr, 5 PM), 
L-phenylalanine (Phe, 2.5 mM) and 3-nitro-L-tyrosine (NO,- Tyr, ~,uM). (B) Serum from a healthy volunteer. (C) Synovial fluid from an osteoarthritic 
patient (the chromatogram of the serum sample was almost identical and again no peak due to nitrotyrosine was detected; the position of the expected 
peak is marked with an arrow). (D) Synovial fluid from a rheumatoid patient showing the presence of 3nitrotyrosine (0.5 ,uM). (E) Synovial fluid 
from the same rheumatoid patient as in (D) was ‘spiked with an equal volume of a mixture of standards (from A above), giving an effective 1 : 1 
dilution. 
Table 1 
3-Nitrotyrosine in body fluids from rheumatoid patients and controls 
Patients [3-Nitrotyrosine] @M) 
In serum 
Range Mean _+ SD. 
In synovial fluid 
Range Mean + S.D. 
Active rheumatoid arthritis (n = 22) *o.o-1.2 0.49 + 0.27 0.1-1.2 0.49 + 0.26 
Osteoarthritis (n = 3) 0 0 0 0 
Early rheumatoid arthritis (n = 6) 0.W.5 0.18 * 0.07 Not available 
Healthy controls (n = 6) 0 0 Not available** 
*Only one RA patient showed a zero value. All differences between active RA and osteoarthritis, early RA or healthy controls were highly significant 
(P <: 0.02). All subjects gave informed consent for samples to be taken and used in research. **It is not ethically acceptable to take synovial fluid 
from normal controls. 
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Fig. 1. (Continued). 
3. Results 
3.1. 3-Nitrotyrosine in body fluids from patients with 
rheumatoid arthritis (RA) 
Peroxynitrite-dependent damage in human body fluids 
nitrates aromatic amino acid residues. In order to inves- 
tigate the occurrence of such damage in patients with 
active RA, we looked for the presence of 3-nitrotyrosine 
in blood serum and in synovial fluid (aspirated from 
inflamed knee joints) using HPLC. 
Fig. 1D shows a representative HPLC chromatogram 
of synovial fluid from a patient with active RA. A well- 
defined peak at the retention time of 3-nitrotyrosine can 
be seen. The identity of this peak was confirmed by three 
methods. First, authentic 3-nitrotyrosine added to the 
samples co-eluted exactly with this peak (Fig. 1E) and 
the height of this peak increased at detector wavelengths 
of 260 nm and at 420 nm, as expected for 3-nitrotyrosine. 
Second, if this fraction was collected, its UV spectrum 
was identical to that of 3-nitrotyrosine showing a maxi- 
mum at 260 nm (HPLC eluent, pH 3.01) and at 420 nm 
(pH 12.0). Third, the collected fraction was freeze-dried 
and analyzed for 3nitrotyrosine by mass spectroscopy 
using direct probe analysis. Characteristic ions of frag- 
mentation of authentic 3-nitrotyrosine observed in this 
fraction were ml the molecular ion = m/z 226, ml + 1 the 
molecular ion plus one = m/z 227 and rn: -COOH and 
NO2 = m/z 135. 
3-Nitrotyrosine was detected in both synovial fluid 
and, at comparable concentrations, in blood plasma, 
from 21 patients with established active RA (Table 1). 
3.2. Control subjects 
As controls for these studies, we used three groups of 
patients. First, we studied patients with osteoa~h~tis, a
largely non-inflammatory joint disease. In no case was 
IL 
any 3-nitrotyrosine detected in serum or synovial fluid 
(Table 1). Fig. 1C shows a representative HPLC chroma- 
togram. Second, patients in the early stages of RA, with- 
out severe joint inflammation, were examined. Synovial 
fluid was not available from these patients. However, 
plasma contained much lower concentrations of 3-nitro- 
tyrosine than those observed in patients with active RA 
(Table 1). Third, serum collected from healthy volunteers 
(n = 6) showed no detectable levels of 3-nitrotyrosine 
(Table 1 and Fig. 1B). 
4. Discussion 
The analyses presented here are highly indicative of 
the presence of 3-nitrotyrosine in body fluids from pa- 
tients with RA. It is not present in control subjects, and 
present only at much lower levels in patients in the early 
stages of RA. Our data provide direct evidence support- 
ing earlier suggestions that NO’ may be a mediator of 
joint damage in chronic inflammatory joint disease [l3- 
17]. Measurement of 3-nitrotyrosine (and possibly of 
other nitro-aromatic compounds) may be a useful way 
of demonstrating NO--mediated pathology and testing 
the effectiveness of therapeutic agents in preventing such 
damage. 
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